肝病时AFP、CA19-9、CA242检测的临床价值探讨

目的：探讨肝病时对肿瘤标志物测定的影响。方法：40例正常人、柏例急性黄疸型肝炎病人、柏例急性无黄疸型肝炎病人、柏例慢性肝炎和柏例肝硬化病人，对这些人群进行肝功能、AFP、CA19—9、CA242等检测。结果：肝功能异常时AFP、CA19-9阳性率较高，高胆红素血症时CA19—9增高明显，肝硬化失代偿期AFP、CA19-9增高明显。结论：肝病时肝功能异常、高胆红素血症以及肝硬化失代偿期对肿瘤标志物测定有较大影响。

Elevation of Serum Tumor Markers (AFP, CA 19-9, CA 242) Levels in Patients with Benign Hepatic Disorders

Objective To investigate the changes of serum levels of several tumor markers （AFP, CA19 - 9, CA242） in patients with benigla hepatic disorders. Methods Liver function tests （serum ALT and total bilirubin） and serum AFP, CA19 -9, CA242 （with CLIA） levels were examined in ①40 controls ②40 patients with icteric acute hepatitis ③40 patients with nonicteric acute hepatitis ④ 40 patients with chronic hepatitis and ⑤ 40 patients with hepatic cirrhosis. Results In patients with increased serum ALT levels （ 132/160）, positive rate of AFP, CA19 - 9 was 46.9% and 40.9% respectively. Positive rate of CA19 - 9 increased markedly （76.5%） in patients with jaundice （68/160）. In decompensated cirrhotic patients （14/40）, AFP and CA19-9 were frequently increased （76.9% and 69.2% ）. Conclusion Moderate increase of serum AFP, CA19 -9 levels was quite common in non - cancer patients with increased serum ALT levels or bilirubin, especially in patients with decempensated cirrhosis. Increase of CA242 in patients with benign hepatic disorders was much less than that of the two other markers.